Zhang D, Shen C, Zhang W, Chen H, Zhao J
Front Immunol. 2025; 16:1524497.
PMID: 40070839
PMC: 11893867.
DOI: 10.3389/fimmu.2025.1524497.
Song S, Tai L, Zhou L, Jiang J, Zhao J
Open Med (Wars). 2025; 20(1):20241136.
PMID: 39927164
PMC: 11806241.
DOI: 10.1515/med-2024-1136.
Li X, Xiong W, Xiong Z, Zhang X
Front Cell Dev Biol. 2025; 13:1521151.
PMID: 39901876
PMC: 11788337.
DOI: 10.3389/fcell.2025.1521151.
Nikolsky K, Kopylov A, Nakhod V, Potoldykova N, Enikeev D, Butkova T
Front Mol Biosci. 2025; 11:1494779.
PMID: 39896931
PMC: 11782039.
DOI: 10.3389/fmolb.2024.1494779.
Karunanayake N, Lu L, Yang H, Geng P, Akin O, Furberg H
Tomography. 2025; 11(1).
PMID: 39852683
PMC: 11769543.
DOI: 10.3390/tomography11010003.
Carbonic Anhydrase IX Targeted Polyaspartamide fluorescent Probes for Tumor imaging.
Zhang Y, Liu F, Shao C, Huang J, Yan G
Int J Nanomedicine. 2025; 20():639-651.
PMID: 39835180
PMC: 11744195.
DOI: 10.2147/IJN.S500614.
The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma.
Quinn A, Bell S, Marrah A, Wakefield M, Fang Y
Cancers (Basel). 2024; 16(23).
PMID: 39682220
PMC: 11640273.
DOI: 10.3390/cancers16234034.
Unveiling the Rare: A Case of Renal Cell Carcinoma Acrometastasis.
Ferraris C, Ishizuka M, Schwartz G
Cureus. 2024; 16(11):e73612.
PMID: 39677123
PMC: 11645174.
DOI: 10.7759/cureus.73612.
Survival rate comparisons of angioembolization and neoadjuvant targeted therapy on unresectable renal cell carcinoma patients: A systematic review.
Muhammad R, Nurfajri D, Dahril D, Ismy J
Urol Ann. 2024; 16(4):251-260.
PMID: 39600579
PMC: 11587945.
DOI: 10.4103/ua.ua_114_23.
Niemann-Pick C1-like 1 as a Prognostic Marker in Renal Cell Carcinoma: A Retrospective Cohort Study.
Kwon R, Kim H, Lee Y, Lee H, Lee S, Park E
Life (Basel). 2024; 14(11).
PMID: 39598242
PMC: 11595514.
DOI: 10.3390/life14111444.
The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers.
Antar R, Fawaz C, Gonzalez D, Xu V, Drouaud A, Krastein J
Curr Oncol. 2024; 31(11):6909-6937.
PMID: 39590142
PMC: 11593205.
DOI: 10.3390/curroncol31110511.
The prognostic value of visible hematuria is only significant in T1a renal cell carcinoma: a single-center retrospective study.
Zhang Y, Li X, Zuo S, Ma X, Chen L, Xiong L
BMC Urol. 2024; 24(1):247.
PMID: 39511512
PMC: 11542408.
DOI: 10.1186/s12894-024-01635-0.
Carcinoembryonic antigen-related cell adhesion molecule 1 in cancer: Blessing or curse?.
Gotz L, Rueckschloss U, Najjar S, Ergun S, Kleefeldt F
Eur J Clin Invest. 2024; 54 Suppl 2:e14337.
PMID: 39451132
PMC: 11646294.
DOI: 10.1111/eci.14337.
Evaluation of prognostic factors for late recurrence in clear cell renal carcinoma: an institutional study.
Voskuil-Galos D, Calinici T, Piciu A, Nemes A
Front Oncol. 2024; 14:1446953.
PMID: 39435283
PMC: 11491331.
DOI: 10.3389/fonc.2024.1446953.
The Power of Images for Prognosis: A Rare Inferior Vena Cava Mass in a Patient With Atypical Symptoms of Heart Failure.
McPherson R, Shehata M, Izquierdo-Pretel G
Cureus. 2024; 16(9):e69411.
PMID: 39403650
PMC: 11472863.
DOI: 10.7759/cureus.69411.
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.
Fleeman N, Houten R, Nevitt S, Mahon J, Beale S, Boland A
Health Technol Assess. 2024; 28(49):1-190.
PMID: 39252678
PMC: 11404358.
DOI: 10.3310/TRRM4238.
SOX11 as a prognostic biomarker linked to m6A modification and immune infiltration in renal clear cell carcinoma.
Wang K, Chen X, Liu Y, Meng X, Zhou L
Transl Cancer Res. 2024; 13(7):3536-3555.
PMID: 39145091
PMC: 11319951.
DOI: 10.21037/tcr-24-109.
Fc receptor-like A promotes malignant behavior in renal cell carcinoma and correlates with tumor immune infiltration.
Liu J, Jiang Y, Liu J, Tian C, Lin Y, Yang Y
Cancer Med. 2024; 13(15):e70072.
PMID: 39108036
PMC: 11303447.
DOI: 10.1002/cam4.70072.
Effective symptom relief through continuous integration of palliative care in advanced renal cell carcinoma patients: comprehensive measurement using the palliative care base assessment.
Dorr A, Vogel I, Wittenbecher F, Westermann J, Thuss-Patience P, Ahn J
Palliat Care Soc Pract. 2024; 18:26323524241260424.
PMID: 39045295
PMC: 11265252.
DOI: 10.1177/26323524241260424.
Cancer marker TNFRSF1A: From single‑cell heterogeneity of renal cell carcinoma to functional validation.
Xu P, Du Z, Xie X, Yang L, Zhang J
Oncol Lett. 2024; 28(3):425.
PMID: 39021735
PMC: 11253100.
DOI: 10.3892/ol.2024.14559.